ClinPGx Blog (Page 35)

Sign in Subscribe

More issues

Clinical evidence support for biomarkers on FDA-approved drug labels

A recent article by Wang et al. in JAMA Internal Medicine reviews the clinical evidence support found on FDA-approved drug labels that are listed on the FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling. The authors found that many labels on the list did not contain, or

ClinGen's GenomeConnect Patient Portal Launches

The NIH-funded Clinical Genome Resource (ClinGen) project has launched its patient portal at GenomeConnect. This site provides a patient registry for those who have already had or are contemplating genetic testing, or have family members who have been tested. It is open to the public for enrollment. Once a

New pathway: Ibuprofen Pharmacodynamics

We have added a new pathway: ibuprofen PD pathway to PharmGKB's pathway collections. Ibuprofen is a traditional non-steroidal anti-inflammatory drug (NSAID) widely used for its analgesic, anti-inflammatory, and anti-pyretic properties. The main mechanism of action of ibuprofen is the non-selective, reversible inhibition of

PharmGKB Wikipedia page

PharmGKB now has a Wikipedia page. The page provides an overview of our purpose, as well as the types of content available on the website. PharmGKB would like to invite the community to add to the page, or email us suggestions for what you think would be useful to include.

The genetics of warfarin dose: focus on African Americans

Warfarin has a narrow therapeutic window, therefore it is important to get the dosage for a patient correct - too low or too high a dose can have dangerous consequences. However, there is large interindividual variability in dose. Incorporation of a patient's genotypes at the polymorphisms CYP2C9*2 (C&

Gemcitabine pathway published in Pharmacogenetics and Genomics

Gemcitabine is a cancer drug used to treat solid tumors as well as certain blood cancers. It can be administered alone or in combination with other drugs as part of a chemotherapy regimen. The genetic variants hypothesized to play a role in the variability of patient response to gemcitabine as

SNP-its Study Summaries

The University of Florida Health Personalized Medicine Program has released "SNP-its" study summaries for pharmacogenomic articles with clinical relevance. The editorial team reviews articles from multiple journals and writes summaries for the ones most relevant to practicing clinicians. Those interested are welcome to subscribe to a monthly

CPIC PEG interferon-alpha guideline now available on guideline.gov

More CPIC PGx-based dosing guidelines are now available on the National Guideline Clearinghouse (NGC) website. NGC is a public resource for evidence-based clinical guidelines, an initiative of the Agency for Healthcare Research and Quality, US Department of Health Services. The most recent CPIC guideline on NGC is: Clinical

New CPIC Guideline: CYP2C9, HLA-B and Phenytoin

Guidelines regarding the use of pharmacogenomic tests for CYP2C9 and HLA-B in dosing phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Phenytoin is broadly used to treat epilepsy, but it has a narrow therapeutic index and wide inter-patient variability. Much

PGx of anti-HIV drug described in new PharmGKB pathway

Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used as part of a highly active anti-retroviral therapy (HAART) regimen against HIV-1 infection. Large variability in EFV plasma levels is observed between patients given the same dose. Genetic variants underlying EFV metabolism have been shown to contribute to